Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

Shares of Kymera KYMR have surged 70.7% in the past three months compared with the industry’s gain of 9.7%. The stock has ...

As new treatments for systemic lupus erythematosus and lupus nephritis enter the armamentarium, revitalizing the management ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

The rate of COVID-related intensive care unit (ICU) admissions was 9.2 per 1,000 person-years among patients who received a monovalent booster and 13.3 per 1,000 person-years for patients who ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 receptor agonist. High-profile endorsements, including from Elon Musk, have ...

RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on ...

Pharvaris' innovative approach to treating hereditary angioedema (HAE) with deucrictibant. Read here for an investment ...

The new Blueprint for Patient-Centered Value Research offers a roadmap for embedding patient voices throughout every stage of ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without ...